Skip to main content
All lobbying clients

NOVOCURE INC.

Lobbying client · New Hampshire · filed 2025 to 2026

Commercial stage oncology dedicated to advancement of TTF therapy to treat solid tumors.

$1,840,000 Reported spend
24 Filings counted
3 Outside firms hired
4 Bills named

Spend is reported income plus in-house expenses across 24 filings. The LDA keeps a separate client record for every registrant that files for a client, so this page adds up 4 records, one per registrant listed below. Records are combined when the client name matches once case, punctuation and endings such as Inc. or LLC are set aside; for a city, county or port the state has to match as well. These filings have also been reported as NOVOCURE.

 Who filed for this client 4

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

 Bills named in these filings 4
  • S. 1717
    Ensuring Patient Access to Critical Breakthrough Products Act of 2025
    11 filings
  • H.R. 5343
    Ensuring Patient Access to Critical Breakthrough Products Act
    10 filings
  • H.R. 1691
    Ensuring Patient Access to Critical Breakthrough Products Act of 2024
    1 filing
  • S. 5349
    Ensuring Patient Access to Critical Breakthrough Products Act of 2024
    1 filing
 Reported by year 2 years
  • 2026 $990,000 12 filings
  • 2025 $850,000 12 filings
 Issues lobbied 7

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 8
  • HOUSE OF REPRESENTATIVES 22
  • SENATE 22
  • Centers For Medicare and Medicaid Services (CMS) 7
  • Health & Human Services, Dept of (HHS) 7
  • U.S. Trade Representative (USTR) 6
  • White House Office 5
  • Food & Drug Administration (FDA) 3
  • Commerce, Dept of (DOC) 2
 Recent filings 24 total
Q3 report
WILLIAMS AND JENSEN, PLLC
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $60,000 income · posted Oct 20, 2026
View → Q3 report
TARPLIN, DOWNS & YOUNG, LLC
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $80,000 income · posted Oct 20, 2026
View → Q3 report
NOVOCURE INC.
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $160,000 expenses · posted Oct 20, 2026
View → Q3 report
MAYER BROWN LLP
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $10,000 income · posted Oct 19, 2026
View → Q2 report
WILLIAMS AND JENSEN, PLLC
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $60,000 income · posted Jul 20, 2026
View → Q2 report
MAYER BROWN LLP
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $20,000 income · posted Jul 20, 2026
View → Q2 report
TARPLIN, DOWNS & YOUNG, LLC
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $80,000 income · posted Jul 20, 2026
View → Q2 report
NOVOCURE INC.
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $160,000 expenses · posted Jul 19, 2026
View → Q1 report
MAYER BROWN LLP
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $40,000 income · posted Apr 20, 2026
View → Q1 report
TARPLIN, DOWNS & YOUNG, LLC
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $80,000 income · posted Apr 20, 2026
View → Q1 report
WILLIAMS AND JENSEN, PLLC
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $60,000 income · posted Apr 20, 2026
View → Q1 report
NOVOCURE INC.
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $180,000 expenses · posted Apr 20, 2026
View → Q4 report
MAYER BROWN LLP
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $30,000 income · posted Jan 21, 2026
View → Registration
MAYER BROWN LLP
4th Quarter 2025 (Oct 1 - Dec 31) · posted Jan 21, 2026
View → Q4 report
TARPLIN, DOWNS & YOUNG, LLC
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $80,000 income · posted Jan 20, 2026
View → Q4 report
WILLIAMS AND JENSEN, PLLC
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $60,000 income · posted Jan 20, 2026
View → Q4 report
NOVOCURE INC.
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $110,000 expenses · posted Jan 17, 2026
View → Registration
WILLIAMS AND JENSEN, PLLC
4th Quarter 2025 (Oct 1 - Dec 31) · posted Nov 20, 2025
View → Q3 report
TARPLIN, DOWNS & YOUNG, LLC
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $80,000 income · posted Oct 15, 2025
View → Q3 report
NOVOCURE INC.
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $110,000 expenses · posted Oct 13, 2025
View →

Showing the 20 most recent of 24 filings. Search the explorer for "NOVOCURE INC.".

 Foreign entities disclosed 4
  • NOVOCURE GMBH Switzerland named on 5 filings · highest disclosed ownership 100% · largest disclosed contribution $0
  • NOVOCURE LUXEMBOURG S.A.R.L. (OWNS 100% OF NOVOCURE GMBH) Luxembourg named on 5 filings · highest disclosed ownership 100% · largest disclosed contribution $0
  • NOVOCURE Switzerland named on 1 filing · highest disclosed ownership 100% · largest disclosed contribution $0
  • NOVOCURE LIMITED (OWNS 100% OF NOVOCURE LUXEMBOURG) Jersey named on 1 filing · highest disclosed ownership 100% · largest disclosed contribution $0

Section 7 of the LD-2: a foreign company or government that owns part of the client, pays toward the lobbying, or benefits from it. Figures are the highest single disclosure across these filings, not a sum: the same stake is re-disclosed each quarter.

Keep going

Filings through , the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem